Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine

doi:10.3748/wjg.v13.i30.4085

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 30

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2375)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

292

HTML

1619

Figures (1-1)

264

Tables (1-3)

200

Sum=2375

Aug 14, 2007 (publication date) through Nov 7, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Aug 14, 2007; 13(30): 4085-4090
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4085

Open in New Tab Full Size Figure Download Figure

Figure 1 Cumulative probability of breakthrough. The cumulative rate of breakthrough tended to differ between HBV DNA > 6.6 log and HBV DNA ≤ 6.6 log group (P = 0.06). The cumulative rate was 88% and 39% after 3 years of lamivudine treatment in HBV DNA > 6.6 log and HBV DNA ≤ 6.6 log group, respectively.

Citation: Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13(30): 4085-4090
URL: https://www.wjgnet.com/1007-9327/full/v13/i30/4085.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i30.4085